What is 5-ALA? Haem synthesis and cellular-energy research
5-ALA means 5-aminolevulinic acid, a precursor in the pathway that produces haem. Haem is part of proteins involved in oxygen handling and electron transfer. This biochemical role explains interest in cellular-energy research, but clinical studies must be read with their particular dose, chemical form and co-ingredients.

Follow the pathway to haem
The body normally makes 5-ALA from glycine and succinyl-CoA. Further reactions, occurring across mitochondria and the cell's cytoplasm, build the ring structure that ultimately incorporates iron to form haem. Haem is familiar as part of haemoglobin, but it also appears in proteins involved in mitochondrial electron transfer. This is why an ingredient associated with haem synthesis can appear in cellular-energy discussions. It is a pathway description, not evidence that adding its precursor will necessarily increase oxygen delivery, ATP production or perceived energy in every person.
Further reading
5-ALA and iron in patient-derived fibroblasts (2019)What laboratory energy experiments measure
A mouse-liver study published in 2011 investigated 5-ALA in relation to cytochrome c oxidase, a haem-containing enzyme complex in the mitochondrial respiratory chain. Researchers reported increased enzyme activity and liver ATP measurements under their experimental conditions. Separately, experiments in fibroblasts from people with mitochondrial diseases have investigated 5-ALA with sodium ferrous citrate. These models examine a pathway in a specific biological setting. They are not trials of daily vitality in healthy consumers, and cell findings should not be converted into a percentage increase in a person's energy.

A human study tested 5-ALA with iron
A 2013 randomised, double-blind trial enrolled 212 adults aged 35–70 with mildly elevated glucose measurements. For 12 weeks, participants received placebo or combinations of 5-ALA phosphate and iron supplied as sodium ferrous citrate. The highest tested combination, 15 mg 5-ALA phosphate with 1.8 mg iron daily, improved selected fasting-glucose and two-hour oral-glucose-tolerance measurements relative to placebo. HbA1c and several other metabolic measures did not change appreciably. The result concerns a combination in a selected population; it is not evidence for treating diabetes or for the effect of 5-ALA alone.
Further reading
Higashikawa et al. (2013): 5-ALA phosphate with ironA tolerance study is a different kind of evidence
A later pilot trial in Bahrain examined escalating doses of 5-ALA phosphate with sodium ferrous citrate in people with type 2 diabetes who were already receiving medication. Its focus was safety and tolerability in a supervised clinical setting. Such work helps define questions for further investigation, but monitoring a small clinical group is not a blanket safety guarantee for unrelated formulas or unsupervised use. It also reinforces a practical point: studies combining an ingredient with iron cannot be used to advise everyone to add iron, which requires its own assessment.

5-ALA is not alpha-lipoic acid
The abbreviation ALA is used for more than one substance. Here, 5-ALA always means 5-aminolevulinic acid. Alpha-lipoic acid is a different compound, and alpha-linolenic acid is a fatty acid; neither should be substituted into this ingredient's evidence. Chemical form matters too. W+NMN Black Gold lists 50 mg 5-aminolevulinic acid phosphate per two capsules. That is the named phosphate ingredient amount, not an invitation to recalculate a different salt or free-acid dose without the relevant chemical and formulation details.
Four ingredients, four identities
Black Gold combines NMN, ergothioneine, 5-ALA phosphate and PQQ disodium salt. The value of describing them separately is clarity: NAD+ metabolism, ergothioneine uptake, haem synthesis and redox research are related aspects of cellular biology, but they are not four measurements of the same effect. No combined clinical outcome follows automatically from that composition. Follow the two-capsule directions rather than adjusting the serving to match a paper. Anyone taking medicines, following a restricted diet or living with a medical condition should discuss the full formula with a healthcare professional.
Your questions, answered.
Should I add iron because a 5-ALA trial used it?
No. Co-administration in a trial is not a personal recommendation. Iron intake should be assessed separately.
Is 5-ALA a synonym for alpha-lipoic acid?
No. They are different compounds, despite the overlapping abbreviation.
Explore the sources.
- Patient-derived cell experiment5-ALA and iron in patient-derived fibroblasts (2019)
- Animal experimentOgura et al. (2011): 5-ALA and mouse-liver energy measurements
- Randomised human combination trialHigashikawa et al. (2013): 5-ALA phosphate with iron
- Supervised human safety trialBahrain pilot trial (2016): 5-ALA phosphate and iron tolerability